Emergent BioSolutions Inc. EBS
6.25 USD -0.19 (-2.95%)
Nov 3, 2026, 3:52 PM EST
5.51 Day range 7.22
4.45 52-week range 13.90
- YTD
- -49.43%
- 1 year
- -40.42%
Analyst view
Consensus: buy
Buy
Price target (mean) 12.00
Ratings (0m) 2 1 buy · 0 hold · 1 sell
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell1
Recommendation trend
- This month 2
- 1 month ago 2
- 2 months ago 2
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.64 | -0.64 – -0.64 | -0.77 | +16.9% | 248.00M | -10.3% | 1 |
| Next quarter | 1.14 | 1.14 – 1.14 | 0.59 | +93.2% | 0 | 0.0% | 1 |
| Current year | -0.81308 | -1.00 – -0.62615 | -6.23 | +87.0% | 1.10B | +4.6% | 2 |
| Next year | 2.07 | 2.07 – 2.07 | -0.81308 | +354.0% | 1.09B | -0.2% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 7, 2024 | Benchmark | Maintained | Buy | Buy |
| Sep 13, 2024 | Rodman & Renshaw | Reiterated | Buy | Buy |
| Aug 22, 2024 | Rodman & Renshaw | Initiated | — | Buy |
| Aug 16, 2024 | Benchmark | Reiterated | Buy | Buy |
| Aug 9, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jul 3, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jul 2, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jun 24, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jun 21, 2024 | Benchmark | Reiterated | Buy | Buy |
| Jun 20, 2024 | Benchmark | Maintained | Buy | Buy |
| Apr 11, 2024 | Benchmark | Reiterated | Buy | Buy |
| Mar 7, 2024 | Benchmark | Upgrade | Hold | Buy |
| Aug 29, 2023 | Benchmark | Downgrade | Buy | Hold |
| May 31, 2023 | Benchmark | Reiterated | Buy | Buy |
| May 19, 2023 | Benchmark | Reiterated | Buy | Buy |
| Apr 10, 2023 | Benchmark | Upgrade | Hold | Buy |
| Mar 17, 2023 | JP Morgan | Downgrade | Neutral | Underweight |
| Nov 10, 2022 | Benchmark | Downgrade | Buy | Hold |
| Nov 9, 2022 | Chardan Capital | Maintained | — | Buy |
| Sep 12, 2022 | Cowen & Co. | Maintained | — | Market Perform |
| May 4, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Apr 29, 2022 | Chardan Capital | Maintained | — | Buy |
| Mar 10, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Nov 10, 2021 | Chardan Capital | Maintained | — | Buy |
| Nov 8, 2021 | Benchmark | Downgrade | Buy | Hold |
| May 5, 2021 | Argus Research | Downgrade | Buy | Hold |
| Apr 30, 2021 | Chardan Capital | Maintained | — | Buy |
| Apr 7, 2021 | Benchmark | Initiated | — | Buy |
| Feb 24, 2021 | Chardan Capital | Upgrade | Neutral | Buy |
| Feb 19, 2021 | Chardan Capital | Downgrade | Buy | Neutral |